Clinical trials: Stenosis Coronary
Aortic Valve Stenosis
RESPOND EDGE Post Market Study
The purpose of the RESPOND EDGE post market study is to collect real world clinical and device performance outcomes data with the Lotus Edge™ Valve System used in routine clinical practice to demonstrate that the commercially…
- Trial name
- RESPOND EDGE (NCT04009720)
- Testing
- Lotus Edge Device
- Where
- 13 sites in Denmark, Finland and 7 more
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- NCT07367724
- Testing
- Ademetionine 1,4-Butanedisulfonate
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- China National Center for Cardiovascular Diseases
Ischemic Heart Disease, Coronary Artery Stenosis
AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis
It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary…
- Conditions
- Ischemic Heart Disease, Coronary Artery Stenosis, Stable Angina Pectoris, Acute Coronary Syndromes
- Trial name
- NCT07579624
- Testing
- single-channel electrocardiogram
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy
This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction ≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber…
- Trial name
- PACE-nHCM (NCT06775886)
- Testing
- myPACE+ algorithm
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Aortic Valve Stenosis
Coronary and Structural Interventions - Transcatheter Aortic Valve Replacement
To evaluate the long-term results after transcatheter aortic valve replacement
- Trial name
- CSI-TAVR (NCT02162069)
- Testing
- CE certified transcatheter ( aortic valve replacement)
- Where
- Germany
- Volunteers
- 843 people
- Sponsor
- University of Ulm
Aortic Valve Stenosis
Cardiovascular Rehabilitation in Patients With Severe Aortic Stenosis Submitted to Valvar Correction
This study will be evaluate the autonomic, endothelial and hemodynamic functions, inspiratory muscle strength, peripheral tissue oxygenation, peripheral and respiratory muscle architecture, and inflammatory profile of severe AS…
- Trial name
- CARE-AS-MOTION (NCT02468219)
- Testing
- cardiovascular rehabilitation program
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- Irmandade Santa Casa de Misericórdia de Porto Alegre
Non-ischemic Cardiomyopathy, Cardiomyopathies
Cardiovascular Multimodality Imaging Study
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis.
- Conditions
- Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy
- Trial name
- NCT06610019
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Montefiore Medical Center
Aortic Stenosis
Assessment of Myocardial Tissue Damage in Aortic Stenosis
Aortic stenosis (AS) is the most common valve disease in the United States and most common indication for valve replacement surgery. Anatomical and hemodynamic severity of AS is insufficient for elucidating patients' prognosis.
- Trial name
- NCT02101619
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Mayo Clinic
Coronary Artery Disease, Coronary Artery Stenoses
Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses
This is a prospective, randomized, controlled, multicenter, open-label study designed to assess whether vFFR is non-inferior to FFR in assessment of intermediate coronary stenosis in terms of the occurrence of MACE during 12…
- Trial name
- LIPSIASTRATEGY (NCT03497637)
- Testing
- Measurement of FFR, Measurement of vFFR
- Where
- 8 sites in Germany
- Volunteers
- 1,054 people
- Sponsor
- Helios Health Institute GmbH
Cerebral Embolization During TAVI Using Balloon-expandable vs. Self-expandable Valves
PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Sentinel™ Device
This prospective, randomized study was designed to analyse the difference of cerebral embolization in patients undergoing transcatheter aortic valve implantation with balloon-expandable vs.
- Trial name
- PROTECT (NCT02895737)
- Testing
- TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra, TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems, TAVI: CoreValve® Evolut R™, CoreValve Medtronic
- Where
- Germany
- Volunteers
- 328 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Aortic Stenosis
Clinical Outcome of Patients With Low-gradient Severe Aortic Stenosis
To assess the ability of baseline clinical parameters and imaging modalities to predict short and long term left ventricular function and clinical outcome of subjects with low-gradient, severe aortic stenosis.
- Trial name
- NCT02010177
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Moderate Aortic Valve Stenosis
The Role of SGLT2i in Management of Moderate AS
Background: The aortic valve is like a door in the heart that lets blood flow out to the body. Over time, this valve can get worn out and become too narrow, leading to a condition called aortic stenosis.
- Trial name
- NCT06469645
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University of East Anglia
Aortic Stenosis, Hypo-attenuated Leaflet Thickening
The HALT Biomarker Study
The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis…
- Conditions
- Aortic Stenosis, Hypo-attenuated Leaflet Thickening, Bioprosthetic Valve Degeneration
- Trial name
- HALT (NCT04552275)
- Testing
- Proteomics Analysis
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Massachusetts General Hospital
Heart Failure, Acute Coronary Syndrome
Platform Therapeutic Education in Heart Failure and Coronary Disease
A first therapeutic education is given before patient's discharge at the hospital, then a dedicated nurse follows patients through the phone,regularly according to patients' needs, continues to give advise on risk factors…
- Conditions
- Heart Failure, Acute Coronary Syndrome, Coronary Bypass Graft Stenosis of Native Artery Graft
- Trial name
- METISCARDIO (NCT01869452)
- Testing
- therapeutic education
- Where
- 4 sites in France
- Volunteers
- 555 people
- Sponsor
- Resicard
Aortic Valve Stenosis
Hydra Registry - Italy Experience
Hydra-IT is a multicenter observational study aim to collect clinical, procedural and follow-up data and evaluate the short, medium and long term results of Hydra TAVI System in patient with severe aortic stenosis.
- Trial name
- NCT05956652
- Testing
- Hydra Transcatheter Aortic Valve System
- Where
- 4 sites in Italy
- Sponsor
- Sahajanand Medical Technologies Limited
Aortic Valve Stenosis, Heart Valve Diseases
Cardiac Function After Minimally Invasive Aortic Valve Implantation
This is a single-center, open-label, randomized controlled trial. Patients scheduled for aortic valve replacement (AVR) at Karolinska University Hospital in Stockholm, Sweden will be eligible.
- Trial name
- CMILE (NCT01972555)
- Testing
- Minimally invasive aortic valve replacement, Conventional aortic valve replacement
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Aortic Valve Stenosis
The Prospective Segeberg TAVI Registry
A single center registry including all patients treated with TAVI at the Heart Center, Bad Segeberg, Germany
- Trial name
- POST-TAVI (NCT03192774)
- Testing
- Transcatheter Aortic Valve Implantation
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Segeberger Kliniken GmbH
Hypertrophic Cardiomyopathy
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
The main objective of the study is to improve implantable cardioverter defibrillator (ICD) implantation decision-making processing relevance by developing a new prediction model of sudden cardiac death (SCD) in hypertrophic…
- Trial name
- OPTIM-HCM (NCT03846297)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Stenosis, Angina Pectoris
Evaluation of the Correlation Between the Coronary Stenosis Degree With FFRCT and the Grade of Stable Angina Pectoris
Angina pectoris is the most common clinical manifestation of coronary heart disease（CHD）, which is the main feature of chest pain caused by transient myocardial ischemia.
- Trial name
- NCT02802046
- Testing
- Computed tomographic angiography of coronary artery
- Volunteers
- 20 people
- Sponsor
- Guiyang No.4 People's Hospital
Hypertrophic Cardiomyopathy (HCM)
Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy
This research study, aims to understand why a specific heart medication called mavacamten works better for some people with hypertrophic cardiomyopathy (HCM) than for others. We believe the answer might be in our genes.
- Trial name
- PRO-Gene Mava (NCT07408427)
- Testing
- Observational study, no new intervention offered
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- University of Manchester
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.